Dr. Reddy's Laboratories announces the First-to-Market launch of the generic version of Ciprodex® (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension, USP in the U.S. Market
HYDERABAD, India & PRINCETON, N.J.: Dr. Reddy’s Laboratories Ltd., along with its subsidiaries together has announced the launch of Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP, a therapeutic equivalent generic version of Ciprodex® (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension, approved by the U.S. Food and Drug Administration (USFDA).
“We are pleased to launch this first-to-market generic product, illustrating our continued commitment to bringing affordable generic medicines to market for patients,” says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s Laboratories. “At the same time, this product demonstrates that we are actively expanding the depth of our portfolio with our first otic suspension dosage form.”
The Ciprodex® brand had U.S. sales of approximately $453 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health*.
Dr. Reddy’s Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP, is available as 7.5 mL fill in a 10 mL bottle.
Please click here for full prescribing information.
Ciprodex® is a trademark of Bayer AG.
*IQVIA Retail and Non-Retail MAT June 2020
RDY-0820-303
